Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

GlobeNewswire

2024-11-13

DesignTx Logo Colored.png

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:

2024 Jefferies London Healthcare Conference
Presentation: Tuesday, November 19, 2024, at 10:00 a.m. GMT
Location: London, UK

Piper Sandler 36^th Annual Healthcare Conference
Fireside Chat: Tuesday, December 3, 2024, at 11:30 a.m. ET
Location: New York, NY

Live webcasts of the presentations will be available here and in the investors section of the company’s website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.

About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2483730002"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483730002\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2483730002?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9bghZNWF49L96eb8GM1KLw--~B/aD0zMjk7dz0xMzY5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/3972332133f117588897c236558bb568","is_english":true,"pubTime":"2024-11-13 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483730002","market":"us","top_or_hot":-1,"title":"Design Therapeutics to Participate in Multiple Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/QkQM47xqSFbqc3ktA0Ie7g--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/756f7355ee3593505f98a201ce9c55ac\" title=\"DesignTx Logo Colored.png\" vspace=\"5\"/>\n<p>CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/DSGN\">Design Therapeutics, Inc.</a> (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:</p>\n<p><strong>2024 Jefferies London Healthcare Conference</strong><br/><strong>Presentation:</strong> Tuesday, November 19, 2024, at 10:00 a.m. GMT<br/><strong>Location: </strong>London, UK<br/><br/></p>\n<p><strong>Piper Sandler 36</strong><sup><strong>th</strong></sup><strong> Annual Healthcare Conference</strong><br/><strong>Fireside Chat: </strong>Tuesday, December 3, 2024, at 11:30 a.m. ET<br/><strong>Location: </strong>New York, NY<br/><br/></p>\n<p>Live webcasts of the presentations will be available here and in the investors section of the company’s website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.</p>\n<p><strong>About Design <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong><br/>Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.<br/></p>\n<p><strong>Contact:</strong><br/>Renee Leck<br/>THRUST Strategic Communications<br/><u>renee@thrustsc.com</u><br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Design Therapeutics to Participate in Multiple Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDesign Therapeutics to Participate in Multiple Upcoming Investor Conferences\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2024-11-13 21:00</span>\n</p>\n</header>\n<article>\n<img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/QkQM47xqSFbqc3ktA0Ie7g--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/756f7355ee3593505f98a201ce9c55ac\" title=\"DesignTx Logo Colored.png\" vspace=\"5\"/>\n<p>CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/DSGN\">Design Therapeutics, Inc.</a> (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:</p>\n<p><strong>2024 Jefferies London Healthcare Conference</strong><br/><strong>Presentation:</strong> Tuesday, November 19, 2024, at 10:00 a.m. GMT<br/><strong>Location: </strong>London, UK<br/><br/></p>\n<p><strong>Piper Sandler 36</strong><sup><strong>th</strong></sup><strong> Annual Healthcare Conference</strong><br/><strong>Fireside Chat: </strong>Tuesday, December 3, 2024, at 11:30 a.m. ET<br/><strong>Location: </strong>New York, NY<br/><br/></p>\n<p>Live webcasts of the presentations will be available here and in the investors section of the company’s website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.</p>\n<p><strong>About Design <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong><br/>Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.<br/></p>\n<p><strong>Contact:</strong><br/>Renee Leck<br/>THRUST Strategic Communications<br/><u>renee@thrustsc.com</u><br/><br/><br/></p>\n<br/>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.yahoo.com/news/design-therapeutics-participate-multiple-upcoming-130000568.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/design-therapeutics-participate-multiple-upcoming-130000568.html","article_id":"2483730002","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9bghZNWF49L96eb8GM1KLw--~B/aD0zMjk7dz0xMzY5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/3972332133f117588897c236558bb568"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483730002","pubTimestamp":1731502800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"CARLSBAD, Calif., Nov. 13, 2024  -- Design Therapeutics, Inc. , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:. Piper Sandler 36th Annual Healthcare ConferenceFireside Chat:Tuesday, December 3, 2024, at 11:30 a.m. ETLocation:New York, NY. Live webcasts of the presentations will be available here and in the investors section of the company’s website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC gene targeted chimera small molecules. The company’s GeneTAC molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTA","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","DSGN":"Design Therapeutics, Inc.","LENZ":"Therapeutics","BK4505":"高瓴资本持仓"},"translate_title":"Design Therapeutics将参加多个即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DSGN":1,"LENZ":1},"content_text":"CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:\n2024 Jefferies London Healthcare ConferencePresentation: Tuesday, November 19, 2024, at 10:00 a.m. GMTLocation: London, UK\nPiper Sandler 36th Annual Healthcare ConferenceFireside Chat: Tuesday, December 3, 2024, at 11:30 a.m. ETLocation: New York, NY\nLive webcasts of the presentations will be available here and in the investors section of the company’s website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.\nAbout Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.\nContact:Renee LeckTHRUST Strategic Communicationsrenee@thrustsc.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1}}}